for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Yabao Pharmaceutical Group Co Ltd

600351.SS

Latest Trade

5.77CNY

Change

-0.07(-1.20%)

Volume

3,610,700

Today's Range

5.74

 - 

5.91

52 Week Range

5.44

 - 

9.14

As of on the Shanghai Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Yabao Pharmaceutical Group sees FY 2018 H1 net profit up 35 pct to 40 pct

July 11(Reuters) - Yabao Pharmaceutical Group Co Ltd <600351.SS> ::Sees FY 2018 H1 net profit to increase by 35 percent to 40 percent, or to increase by 37.5 million yuan to 42.9 million yuan.Says FY 2017 H1 net profit was 107.1 million yuan.The reason for the forecast is increased main products profit .

Yabao Pharmaceutical Group to pay cash dividend of 0.1 yuan per share on June 20

June 13 (Reuters) - Yabao Pharmaceutical Group Co Ltd <600351.SS>:Says it will pay a cash dividend of 0.1 yuan per share (before tax) for 2017 to shareholders of record on June 19.The company's shares will be traded ex-right and ex-dividend on June 20 and the dividend will be paid on June 20 .

Yabao Pharmaceutical Group sees FY 2017 net profit to up 60 pct to 80 pct

Jan 26(Reuters) - Yabao Pharmaceutical Group Co Ltd <600351.SS> ::Says net profit for FY 2017 to up 60 percent to 80 percent.Says FY 2016 net profit was 222.2 million yuan .

Yabao Pharma Sees 2017 Net Profit Up 788-818 Pct On Rising Sales Of High Margin Products

Dec 25 (Reuters) - Yabao Pharmaceutical Group Co Ltd <600351.SS>::SAYS IT SEES 2017 NET PROFIT UP 788-818 PERCENT Y/Y FROM 225.2 MILLION YUAN ($34.44 million) YEAR AGO.

Yabao Pharmaceutical Group sees 2017 Q1-Q3 net profit to increase by 100 pct to 120 pct

Sept 27(Reuters) - Yabao Pharmaceutical Group Co Ltd <600351.SS> ::* Says net profit for 2017 Q1-Q3 to increase by 100 percent to 120 percent, compared to net profit of 2016 Q1-Q3 (68.8 million yuan).* Says increased sales revenue as main reason for the forecast.

Yabao Pharmaceutical Group gets approval to conduct drug clinical trials for diabetes

July 29 (Reuters) - Yabao Pharmaceutical Group Co Ltd <600351.SS>:* Says it gets an approval to conduct drug clinical trials of SY-008 which can be used for treatment of diabetes, from China Food and Drug Administration.

Yabao Pharmaceutical Group sees FY 2016 net profit down 70 pct to 90 pct

Yabao Pharmaceutical Group <600351.SS> :Says it sees 2016 net profit down 70 percent to 90 percent, from a year ago.

Yabao Pharmaceutical Group sees 2016 Q1~Q3 net profit to decrease by 50 pct to 70 pct

Yabao Pharmaceutical Group Co Ltd <600351.SS> :sees 2016 Q1~Q3 net profit to decrease by 50 percent to 70 percent, compared to net profit of Q1~Q3 in 2015(206.7 million yuan).

Yabao Pharmaceutical Group appoints Grant Thornton as new auditor for 2016

Yabao Pharmaceutical Group <600351.SS>:Says it appoints Grant Thornton as new auditor for 2016.

Yabao Pharmaceutical Group to buy 75 pct stake in Shanghai Qingsong Pharmacy at 611.8 mln yuan

Yabao Pharmaceutical Group <600351.SS>:Says it will buy 75 percent stake in Shanghai Qingsong Pharmacy Co Ltd at 611.8 million yuan.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up